You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Medical history ongoing at baseline (MITT/cIAI population and mMITT/cUTI population)

From: Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam

System organ class, n (%)a Diabetes No diabetes Differenceb;
 Preferred term n = 198 n = 1408 P value
Cardiac disorders 50 (25.3) 177 (12.6) −12.7; <0.00001
 Coronary artery disorders 34 (17.2) 107 (7.6) −9.6; <0.00001
 Heart failures 15 (7.6) 39 (2.8) −4.8; 0.00045
Endocrine disorders 17 (8.6) 57 (4.0) −4.5; 0.00436
 Hypothyroidism 14 (7.1) 41 (2.9) −4.2; 0.00260
Eye disorders 14 (7.1) 33 (2.3) −4.7; 0.00022
 Diabetic retinopathy 9 (4.5) 0 −4.5; <0.00001
Hepatobiliary disorders 21 (10.6) 82 (5.8) −4.8; 0.01014
 Hepatic and hepatobiliary disorders 13 (6.6) 30 (2.1) −4.4; 0.00030
Infections and infestations 55 (27.8) 228 (16.2) −11.6; 0.00006
 Urinary tract infections 35 (17.7) 119 (8.5) −9.2; 0.00004
 Viral infectious disorders 10 (5.1) 25 (1.8) −3.3; 0.00313
Metabolism and nutrition disorders 198 (100.0) 166 (11.8) −88.2; <0.00001
 Glucose metabolism disorders, including diabetes 198 (100.0) 16 (1.1) −98.9; <0.00001
 Lipid metabolism disorders 31 (15.7) 62 (4.4) −11.3; <0.00001
 Obesity 13 (6.6) 37 (2.6) −3.9; 0.00282
Musculoskeletal and connective tissue disorders 32 (16.2) 114 (8.1) −8.1; 0.00022
 Joint disorders 23 (11.6) 64 (4.5) −7.1; 0.00004
Nervous system disorders 34 (17.2) 99 (7.0) −10.1; <0.00001
 Peripheral neuropathies 17 (8.6) 1 (0.1) −8.5; <0.00001
Psychiatric disorders 22 (11.1) 79 (5.6) −5.5; 0.00284
 Depressive disorders 13 (6.6) 33 (2.3) −4.2; 0.00086
Renal and urinary disorders 67 (33.8) 245 (17.4) −16.4; <0.00001
 Chronic kidney disease 17 (8.6) 19 (1.3) −7.2; <0.00001
 Diabetic nephropathy 12 (6.1) 0 (0.0) −6.1; <0.00001
 Urolithiases 22 (11.1) 81 (5.8) −5.4; 0.00397
Respiratory, thoracic, and mediastinal disorders 28 (14.1) 87 (6.2) −8.0; 0.00005
 Bronchospasm and obstruction 17 (8.6) 49 (3.5) −5.1; 0.0007
Vascular disorders 140 (70.7) 390 (27.7) −43.0; <0.00001
 Hypertension 131 (66.2) 342 (24.3) −41.9; <0.00001
  1. cIAI complicated intra-abdominal infection, cUTI complicated urinary tract infection, MITT microbiologic intention-to-treat, mMITT modified microbiologic intention-to-treat
  2. aOnly preferred terms with differences in rates between patients with and without diabetes are presented
  3. bPercentage difference calculated for patients with history of diabetes compared with those with no history of diabetes